Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:32 ET | 2256 | 15.2 |
09:34 ET | 100 | 15.25 |
09:36 ET | 500 | 15.17 |
09:41 ET | 370 | 15.06 |
09:43 ET | 1842 | 14.93 |
09:48 ET | 500 | 15.12 |
09:50 ET | 400 | 15.2 |
09:52 ET | 100 | 15.2 |
09:54 ET | 100 | 15.2 |
09:56 ET | 200 | 15.19 |
09:59 ET | 100 | 15.19 |
10:01 ET | 400 | 15.085 |
10:03 ET | 300 | 15.085 |
10:06 ET | 400 | 14.985 |
10:12 ET | 200 | 14.97 |
10:14 ET | 100 | 14.96 |
10:17 ET | 700 | 14.905 |
10:19 ET | 100 | 14.905 |
10:21 ET | 400 | 14.875 |
10:28 ET | 1026 | 14.895 |
10:30 ET | 600 | 14.895 |
10:33 ET | 600 | 14.9 |
10:37 ET | 100 | 14.91 |
10:39 ET | 100 | 14.92 |
10:42 ET | 102 | 14.875 |
10:51 ET | 1330 | 14.96 |
10:53 ET | 1350 | 15 |
10:55 ET | 4477 | 15.05 |
11:08 ET | 100 | 15.025 |
11:09 ET | 100 | 15.07 |
11:11 ET | 600 | 14.99 |
11:27 ET | 101 | 15.06 |
11:29 ET | 1214 | 15.06 |
11:31 ET | 630 | 15 |
11:33 ET | 100 | 14.98 |
11:40 ET | 100 | 14.94 |
11:42 ET | 200 | 14.98 |
11:45 ET | 100 | 14.98 |
11:56 ET | 450 | 14.89 |
11:58 ET | 125 | 14.8505 |
12:12 ET | 400 | 14.92 |
12:14 ET | 215 | 14.95 |
12:16 ET | 108 | 14.97 |
12:20 ET | 100 | 14.9 |
12:23 ET | 100 | 14.97 |
12:25 ET | 943 | 14.92 |
12:27 ET | 403 | 14.92 |
12:30 ET | 100 | 14.97 |
12:48 ET | 100 | 14.945 |
12:54 ET | 329 | 14.96 |
12:56 ET | 200 | 14.94 |
01:03 ET | 200 | 14.92 |
01:17 ET | 700 | 14.95 |
01:21 ET | 100 | 14.97 |
01:35 ET | 200 | 15.01 |
01:44 ET | 100 | 15.01 |
01:46 ET | 100 | 15.01 |
01:50 ET | 100 | 14.98 |
01:53 ET | 100 | 14.99 |
01:57 ET | 400 | 15.02 |
02:00 ET | 100 | 15.005 |
02:04 ET | 400 | 15.05 |
02:08 ET | 200 | 15.08 |
02:09 ET | 100 | 15.06 |
02:11 ET | 200 | 15.06 |
02:13 ET | 100 | 15.075 |
02:15 ET | 946 | 15 |
02:18 ET | 100 | 15.04 |
02:20 ET | 300 | 15 |
02:24 ET | 300 | 14.95 |
02:29 ET | 100 | 14.935 |
02:33 ET | 284 | 14.9053 |
02:36 ET | 200 | 14.88 |
02:47 ET | 1094 | 14.82 |
02:49 ET | 100 | 14.87 |
02:51 ET | 904 | 14.78 |
02:54 ET | 100 | 14.79 |
02:56 ET | 248 | 14.7677 |
03:00 ET | 1587 | 14.75 |
03:02 ET | 959 | 14.6603 |
03:03 ET | 100 | 14.7 |
03:07 ET | 1200 | 14.71 |
03:09 ET | 600 | 14.69 |
03:14 ET | 300 | 14.71 |
03:18 ET | 1600 | 14.7 |
03:21 ET | 200 | 14.74 |
03:25 ET | 599 | 14.675 |
03:27 ET | 100 | 14.67 |
03:30 ET | 100 | 14.71 |
03:32 ET | 250 | 14.705 |
03:34 ET | 100 | 14.7 |
03:36 ET | 100 | 14.67 |
03:38 ET | 400 | 14.655 |
03:39 ET | 425 | 14.63 |
03:41 ET | 1950 | 14.645 |
03:43 ET | 1214 | 14.61 |
03:45 ET | 300 | 14.61 |
03:48 ET | 816 | 14.57 |
03:50 ET | 916 | 14.58 |
03:52 ET | 379 | 14.59 |
03:54 ET | 825 | 14.63 |
03:56 ET | 2406 | 14.64 |
03:57 ET | 704 | 14.62 |
03:59 ET | 14527 | 14.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 527.6M | -5.2x | --- |
Terns Pharmaceuticals Inc | 530.4M | -6.3x | --- |
Corbus Pharmaceuticals Holdings Inc | 535.4M | -6.3x | --- |
Erasca Inc | 516.4M | -2.4x | --- |
Cabaletta Bio Inc | 514.6M | -5.4x | --- |
Replimune Group Inc | 513.7M | -2.4x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $527.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-2.79 |
Book Value | $5.48 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.